基于网络药理学研究桑黄酮G治疗糖尿病性脑病作用机制研究

doi:10.5246/jcps.2025.03.019

摘要/Abstract

摘要：

本研究旨在通过采用网络药理学研究桑黄酮G治疗糖尿病脑病的作用机制。通过Pharmmapper数据库确定桑黄酮G的作用靶点, GeneCards database, DisGeNET和Therapeutic Target等数据库筛选糖尿病脑病的潜在靶点。利用STRING 12.0进行蛋白质互作分析, 构建PPI网络以筛选重要靶点; 运用David数据库对靶点进行GO和KEGG富集分析, 运用Cytoscape软件筛选出关键基因。结果显示桑黄酮G有101个潜在靶点, 糖尿病脑病共有1058个潜在靶点。两者有34个共同靶基因。GSK3B、CASP3、MAKP14、ESR1和PPARG被认为是桑黄酮G治疗糖尿病脑病的关键基因。KEGG富集通路的分析显示, 桑黄酮G治疗糖尿病脑病的主要通路包括调节脂质与动脉粥样硬化、流体剪切应力与动脉粥样硬化相关通路、IL-17信号通路和AGE-RAGE信号通路。本研究表明桑黄酮G可以通过多靶点、多通路改善糖尿病脑病, 为进一步研究糖尿病脑病的治疗提供了新的思路。

关键词: 桑黄酮G, 网络药理学, 糖尿病脑病, 作用机制

Abstract:

The present study employed network pharmacology to elucidate the molecular mechanism underlying the therapeutic effects of kuwanon G in diabetic encephalopathy. Utilizing the Pharmmapper databases, we identified potential targets associated with kuwanon G. Simultaneously, targets related to diabetic encephalopathy were screened. The VENNY software facilitated the identification of 34 common target genes, forming the basis for constructing a protein-protein interaction network map via the STRING database. GO enrichment and KEGG pathway analyses were conducted using the David database, with Cytoscape software employed to pinpoint key target genes. Results revealed 101 potential targets for kuwanon G and 1058 for diabetic encephalopathy, with an overlap of 34 target genes. Notably, GSK3B, CASP3, MAKP14, ESR1, and PPARG emerged as pivotal genes in the therapeutic action of kuwanon G against diabetic encephalopathy. Pathway analysis of these key genes indicated that kuwanon G exerted its therapeutic effects through modulating pathways associated with lipid and atherosclerosis, fluid shear stress and atherosclerosis, IL-17 signaling, and the AGE-RAGE signaling pathway. This study offered valuable insights into the potential molecular mechanisms of kuwanon G in treating diabetic encephalopathy, presenting a novel framework for future research in this domain.

Key words: Kuwanon G, Network pharmacology, Diabetic encephalopathy, Mechanism

Supporting:

张玉倩, 牛海英, 张晓炜, 解伟伟, 张恺玥, 张兰桐, 靳怡然. 基于网络药理学研究桑黄酮G治疗糖尿病性脑病作用机制研究[J]. 中国药学(英文版), 2025, 34(3): 251-259.

Yuqian Zhang, Haiying Niu, Xiaowei Zhang, Weiwei Xie, Kaiyue Zhang, Lantong Zhang, Yiran Jin. Elucidating the mechanism of Kuwanon G in treating diabetic encephalopathy through network pharmacology: A comprehensive study[J]. Journal of Chinese Pharmaceutical Sciences, 2025, 34(3): 251-259.

图/表 5

Figure 1. The 2D structural diagram of kuwanon G.

Figure 2. Venn diagram of disease and drug targets.

Figure 3. PPI network diagram of key targets.

Figure 4. GO enrichment analysis of targets. Figure 4A and 4B are the barplot and dotplot, respectively.

Figure 5. KEGG pathway analyses of targets.

参考文献 28

[1]	International Diabetes Federation. IDF Diabetes Atlas-7th Edition [EB/OL]. http://www.diabetesatlas.org, 2021-06-08.
[2]	Markowicz-Piasecka, M.; Sikora, J.; Szydłowska, A.; Skupień, A.; Mikiciuk-Olasik, E.; Huttunen, K.M. Metformin-A future therapy for neurodegenerative diseases: Theme: Drug Discovery, Development and Delivery in Alzheimer’s Disease Guest Editor: Davide Brambilla. Pharm. Res. 2017, 34, 2614–2627.
[3]	Bogush, M.; Heldt, N.A.; Persidsky, Y. Blood brain barrier injury in diabetes: unrecognized effects on brain and cognition. J. Neuroimmune Pharmacol. 2017, 12, 593–601.
[4]	Abou-El-Hassan, H.; Dia, B.; Choucair, K.; Eid, S.A.; Najdi, F.; Baki, L.; Talih, F.; Eid, A.A.; Kobeissy, F. Traumatic brain injury, diabetic neuropathy and altered-psychiatric health: The fateful triangle. Med. Hypotheses. 2017, 108, 69–80.
[5]	Belanger, A.; Lavoie, N.; Trudeau, F.; Massicotte, G.; Gagnon, S. Preserved LTP and water maze learning in hyperglycaemic–hyperinsulinemic ZDF rats. Physiol. Behav. 2004, 83, 483–494.
[6]	Zeng, W.Y.; Suo, Y.R.; Li, H.H.; Wei, B.; Sun, Y.X.; Yang, L.; Jiang, X.J. Research progress of active components of traditional Chinese medicine on prevention of diabetic cognitive deficits. Liaoning J. Tradit. Chin. Med. 2017, 44, 2667–2671.
[7]	Zhou, L.P.; Zhamg, X.K.; Wang, F. Experimental Research Progress on Prevention and Treatment of Cognitive Dysfunction in Diabetes Mellitusby Traditional Chinese Medicine. Chin. J. Exp. Tradit. Med. Form. 2019, 25, 227–234.
[8]	Jung, H.W.; Kang, S.Y.; Kang, J.S.; Kim, A.R.; Woo, E.R.; Park, Y.K. Effect of Kuwanon G isolated from the root bark of Morus alba on ovalbumin-induced allergic response in a mouse model of asthma. Phytother. Res. 2014, 28, 1713–1719.
[9]	Liu, X.X.; Zhang, X.W.; Wang, K.; Wang, X.Y.; Ma, W.L.; Cao, W.; Mo, D.; Sun, Y.; Li, X.Q. Kuwanon G attenuates atherosclerosis by upregulation of LXRα-ABCA1/ABCG1 and inhibition of NFκB activity in macrophages. Toxicol. Appl. Pharmacol. 2018, 341, 56–63.
[10]	Gan, W.J.; Gao, C.L.; Zhang, W.Q.; Gu, J.L.; Zhao, T.T.; Guo, H.L.; Zhou, H.; Xu, Y.; Yu, L.L.; Li, L.F.; Gui, D.K.; Xu, Y.H. Kuwanon G protects HT22 cells from advanced glycation end product-induced damage. Exp. Ther. Med. 2021, 21, 425.
[11]	Yang, T.; Chen, X.; Mei, Z.; Liu, X.; Feng, Z.; Liao, J.; Deng, Y.; Ge, J. An integrated analysis of network pharmacology and experimental validation to reveal the mechanism of Chinese medicine formula Naotaifang in treating cerebral ischemia-reperfusion injury. Drug Des. Devel. Ther. 2021, 15, 3783–3808.
[12]	Dong, Y.; Hao, L.; Fang, K.; Han, X.X.; Yu, H.; Zhang, J.J.; Cai, L.J.; Fan, T.; Zhang, W.D.; Pang, K.; Ma, W.M.; Wang, X.T.; Han, C.H. A network pharmacology perspective for deciphering potential mechanisms of action of Solanum nigrum L. in bladder cancer. BMC Complement. Med. Ther. 2021, 21, 45.
[13]	Llorens-MarÃtin, M.; Jurado, J.; HernÃ¡ndez, F.; Ãvila, J. GSK-3β, a pivotal kinase in Alzheimer disease. Front. Mol. Neurosci. 2014, 7, 46.
[14]	Engel, T.; Lucas, J.J.; Gómez-Ramos, P.; Moran, M.A.; Ávila, J.; Hernández, F. Cooexpression of FTDP-17 tau and GSK-3β in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol. Aging. 2006, 27, 1258–1268.
[15]	Su, J.H.; Zhao, M.; Anderson, A.J.; Srinivasan, A.; Cotman, C.W. Activated caspase-3 expression in Alzheimer’s and aged control brain: correlation with Alzheimer pathology. Brain Res. 2001, 898, 350–357.
[16]	Płóciennik, A.; Prendecki, M.; Zuba, E.; Siudzinski, M.; Dorszewska, J. Activated caspase-3 and neurodegeneration and synaptic plasticity in Alzheimer’s disease. Adv. Alzheimers. Dis. 2015, 4, 63–77.
[17]	Maphis, N.; Jiang, S.Y.; Xu, G.X.; Kokiko-Cochran, O.N.; Roy, S.M.; Van Eldik, L.J.; Watterson, D.M.; Lamb, B.T.; Bhaskar, K. Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology. Alzheimers. Res. Ther. 2016, 8, 54.
[18]	Schnöder, L.; Gasparoni, G.; Nordström, K.; Schottek, A.; Tomic, I.; Christmann, A.; Schäfer, K.H.; Menger, M.D.; Walter, J.; Fassbender, K.; Liu, Y. Neuronal deficiency of p38α-MAPK ameliorates symptoms and pathology of APP or Tau-transgenic Alzheimer’s mouse models. FASEB J. 2020, 34, 9628–9649.
[19]	Zhou, Y.L.; Du, Y.F.; Du, H.; Shao, P. Insulin resistance in Alzheimer’s disease (AD) mouse intestinal macrophages is mediated by activation of JNK. Eur. Rev. Med. Pharmaco. 2017, 21, 1787–1794.
[20]	Christiansen, A.R.; Lipshultz, L.I.; Hotaling, J.M. Selective androgenreceptor modulators: the future of androgen therapy? Transl. Androl. Urol. 2020, 9, 135–148.
[21]	Khan, M.A.; Alam, Q.; Haque, A.; Ashafaq, M.; Khan, M.J.; Ashraf, G.M.; Ahmad, M. Current progress on peroxisome proliferator-activated receptor gamma agonist as an emerging therapeutic approach for the treatment of Alzheimer’s disease: an update. Curr. Neuropharmacol. 2019, 17, 232–246.
[22]	Mohseni-Moghaddam, P.; Ghobadian, R.; Khaleghzadeh-Ahangar, H. Dementia in diabetes mellitus and atherosclerosis: Two interrelated systemic diseases. Brain Res. Bull. 2022, 181, 87–96.
[23]	Shen, C.Y.; Lu, C.H.; Wu, C.H.; Li, K.J.; Kuo, Y.M.; Hsieh, S.C.; Yu, C.L. The development of Maillard reaction, and advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling inhibitors as novel therapeutic strategies for patients with AGE-related diseases. Molecules. 2020, 25, 5591.
[24]	Byun, K.; Yoo, Y.; Son, M.; Lee, J.; Jeong, G.B.; Park, Y.M.; Salekdeh, G.H.; Lee, B. Advanced glycation end-products produced systemically and by macrophages: a common contributor to inflammation and degenerative diseases. Pharmacol. Ther. 2017, 177, 44–55.
[25]	de Retana, S.F.; Marazuela, P.; Solé, M.; Colell, G.; Bonaterra, A.; Sánchez-Quesada, J.L.; Montaner, J.; Maspoch, D.; Cano-Sarabia, M.; Hernández-Guillamon, M. Peripheral administration of human recombinant ApoJ/clusterin modulates brain beta-amyloid levels in APP23 mice. Alzheimers Res. Ther. 2019, 11, 42.
[26]	Yang, H.M.; Xie, T.T.; Li, D.R.; Du, X.H.; Wang, T.X.; Li, C.Y.; Song, X.J.; Xu, L.Q.; Yi, F.; Liang, X.H.; Gao, L.F.; Yang, X.D.; Ma, C.H. Tim-3 aggravates podocyte injury in diabetic nephropathy by promoting macrophage activation via the NF-κB/TNF-α pathway. Mol. Metab. 2019, 23, 24–36.
[27]	Gabbouj, S.; Ryhänen, S.; Marttinen, M.; Wittrahm, R.; Takalo, M.; Kemppainen, S.; Martiskainen, H.; Tanila, H.; Haapasalo, A.; Hiltunen, M.; Natunen, T. Altered insulin signaling in Alzheimer’s disease brain–special emphasis on PI3K-Akt pathway. Front. Neurosci. 2019, 13, 629.
[28]	Su, F.; Shu, H.; Ye, Q.; Wang, Z.; Xie, C.; Yuan, B.; Zhang, Z.; Bai, F. Brain insulin resistance deteriorates cognition by altering the topological features of brain networks. Neuroimage Clin. 2017, 13, 280–287.